+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Jevtana"

Global Prostate Cancer Therapeutics Market - Product Thumbnail Image

Global Prostate Cancer Therapeutics Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
From
Drug Overview: Jevtana - Product Thumbnail Image

Drug Overview: Jevtana

  • Drug Pipelines
  • January 2018
  • 16 Pages
  • Global
From
Jevtana Kit - API Insight, 2022 - Product Thumbnail Image

Jevtana Kit - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Jevtana Kit- Drug Insight, 2019 - Product Thumbnail Image

Jevtana Kit- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 12 Results (Page 1 of 1)
Loading Indicator

Jevtana is a chemotherapy drug used to treat metastatic castration-resistant prostate cancer (mCRPC). It is a type of docetaxel, a chemotherapy drug that works by stopping cancer cells from dividing and growing. Jevtana is administered as an intravenous infusion every three weeks. It is used in combination with prednisone, a steroid that helps reduce inflammation and swelling. Jevtana is approved by the US Food and Drug Administration (FDA) for the treatment of mCRPC in men who have already received other treatments. It is also approved in the European Union and other countries. The Jevtana market is highly competitive, with several companies offering similar products. These include Sanofi, Pfizer, Astellas Pharma, and Takeda Pharmaceuticals. Each company has its own unique product offering, with different formulations, dosages, and delivery methods. The Jevtana market is an important part of the prostate cancer drug market, providing an important treatment option for men with mCRPC. Companies in the market are continually striving to improve their products and provide better outcomes for patients. Show Less Read more